Randomized, placebo-controlled Phase I study of SJP-0008 in healthy adult volunteers (single and repeated dose study)
Latest Information Update: 14 Apr 2022
At a glance
- Drugs SJP 0008 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Senju Pharmaceutical
Most Recent Events
- 28 Jul 2016 Status changed from recruiting to completed.
- 29 Sep 2015 New trial record